key: cord-0871245-p4nxn4ww
authors: Sharun, Khan; Tiwari, Ruchi; Dhama, Kuldeep; Emran, Talha Bin; Rabaan, Ali A.; Al Mutair, Abbas
title: Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies
date: 2021-06-23
journal: Human vaccines & immunotherapeutics
DOI: 10.1080/21645515.2021.1923350
sha: 05ca9a9cda2cb3fa308455ebe38f6b292b894245
doc_id: 871245
cord_uid: p4nxn4ww

The genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been emerging and circulating in different parts of the world from the beginning of the coronavirus disease (COVID-19) pandemic. Variants are divided into three classes: variant of interest, variant of concern, and variant of high consequence depending on its impact on the transmission, disease severity, diagnostics, vaccines, and therapeutics. The variants of concern include the United Kingdom variant (B.1.1.7), South Africa variant (B.1.351), two related California variants (B.1.427 and B.1.429), and Brazil variant (P.1). These SARS-CoV-2 variants have a direct impact on the available COVID-19 vaccines and immunotherapeutics as they can alter the neutralizing activity of vaccine-elicited antibodies and monoclonal antibodies resulting in mild-to-substantial loss of efficacy. There is a need to establish surveillance systems that can monitor the emergence of novel SARS-CoV-2 variants worldwide.

Coronavirus disease , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has already affected 131.3 millions 1 people, resulting in the death of 2.8 million 1 individuals globally as of April 4, 2021. SARS-CoV-2 has spread rapidly worldwide over the past 1 year, causing clusters of cases that can be linked to the importation of cases across international borders, mainly via air travel. 1 Although RNA viruses are reported to accumulate mutations rapidly because they replicate inside their hosts, SARS-CoV-2 mutates much slower than other RNA viruses. The nucleotide substitution rate of SARS-CoV-2 roughly estimates to 1 × 10 −3 substitutions per year, almost similar to that of the Ebola virus (1.42 × 10 −3 ). 2 Coronaviruses, including SARS-CoV-2, can generate novel variants by accumulating point mutations, recombination, insertions, and deletions within the genome. Such changes might a have direct impact on the pathogenesis, transmission potential, and disease severity. Furthermore, mutations in the spike protein can alter the interaction with human cell-surface angiotensin-converting enzyme 2 receptors. 2 Since the beginning of this pandemic, genetic variants of SARS-CoV-2 have been emerging and circulating in different parts of the world. However, toward the end of 2020, several novel variants with superior transmission potential and infectivity have been reported, which were associated with a severe form of the disease. 3 These variants had one or more mutations/spike protein substitutions that helped to differentiate them from other variants in circulation. For ease of understanding, these variants were divided into three classes: variant of interest, variant of concern (VOC), and variant of high consequence (Table 1 ). 3 The inclusion of a novel variant into one of these classes depends on its impact on transmission, disease severity, diagnostics, vaccines, and therapeutics. Therefore, the status of a variant might escalate or de-escalate depending on the most recent scientific evidence.

As 3 Compared to the SARS-CoV-2 Wuhan reference sequence, all current VOCs have the D614G substitution (Table 1) . SARS-CoV-2 containing the D614G substitution in the spike protein is the predominant circulating variant. Experimental studies have confirmed that the SARS-CoV-2 variant containing D614G substitution has enhanced ACE2-binding ability, with increased replication in human ACE2 knock-in mouse model and in vitro cultures (nasal airway epithelial and primary human bronchial cultures). 4 D614G substitution was also found to enhance the replication and transmissibility of SARS-CoV-2 in hamster and ferret models. 4 In addition to the human-to-human transmission, the rapid transmission of SARS-CoV-2 in non-human hosts such as farmed minks can result in the emergence of novel variants that can later transmit back to humans. 5 The mink-associated variant identified in both minks and humans was later referred to as "Cluster 5." However, only 12 human cases have been reported in Denmark. 6 Owing to efficient preventive measures, such as the implementation of lockdown and mass testing, Cluster 5 The variant has higher reproduction number than that of preexisting variants. 7 The variant binds with ACE2 with two-fold greater affinity than the original receptor binding domain. 8 The risk of mortality is increased compared with that associated with previously circulating variants. 9 The presence of E484K mutation in B. This variant is associated with ~50% increased transmission. 14 Reduction in the neutralization capacity of sera from mRNA-1273 vaccinated individuals was observed. 15 The neutralizing activity of the sera was found to be significantly lowered in mRNA-1273 ( is not in circulation in the human population and is therefore considered extinct. SARS-CoV-2 variants, especially VOCs, pose a threat to the ongoing efforts to control the COVID-19 pandemic. Some of the variants may even possess superior transmission potential, altered pathogenesis and disease severity and can be linked to the rapid increase in COVID-19 cases and associated hospitalization. The VOCs have a direct impact on the available COVID-19 vaccines and immunotherapeutics by altering the neutralizing activity of vaccine-elicited antibodies and monoclonal antibodies resulting in mild-to-substantial loss of efficacy. Currently, there are no SARS-CoV-2 variants having the potential to attain the level of high consequence to be classified under "variant of high consequence." However, the possibility of the emergence of such a variant cannot be excluded in the future. Therefore, it is necessary to establish surveillance systems that can monitor the emergence of novel SARS-CoV-2 variants worldwide. This will ensure that even if novel variants of high consequence emerge, they can be prevented from spreading globally by implementing prevention and control measures at an early stage. 

No potential conflicts of interest were disclosed.

KS and KD conceptualized the manuscript; KS wrote the first draft with input from KD. RT, TBE, AAR and AAM reviewed and updated the manuscript. All authors contributed to revisions and approved the final manuscript. 

International travel during the COVID-19 pandemic: implications and risks associated with "travel bubbles

Covid-19: variants and vaccination

Centre for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions. CDC; 2021

SARS-CoV-2 spike D614G change enhances replication and transmission

SARS-CoV-2 variants lacking ORF8 occurred in farmed mink and pangolin

SARS-CoV-2 infection in farmed minks, associated zoonotic concerns, and importance of the one health approach during the ongoing COVID-19 pandemic

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. (80-)

SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants bind human ACE2 with increased affinity. bioRxiv

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B 1.1.7 variant of SARS-CoV-2

Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 variant 501Y.V2

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature

ChAdOx1 nCoV-19 (AZD1222) protects hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 1 disease. bioRxiv

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv

Detection of SARS-CoV-2 lineage P.1 in patients from a region with exponentially increasing hospitalization rates in

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies. bioRxiv

A novel SARS-CoV-2 variant of concern, B.1.526, identified in New York. medRxiv Prepr Serv Heal Sci